Acturis Canada has secured a key endorsement from the Center for Study of Insurance Operations (CSIO), achieving API Security ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it will charge the same in the UK for new schizophrenia drug Cobenfy as in the ...

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

A wide of array of advanced controllers arrived in 2025, marked by high integration and enhanced intelligence in solutions ...

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

Rheumatologists share how they are using AI platforms for clinical documentation, reducing EHR time, streamlining workflows, ...

CSIO congratulates Acturis Canada Inc. (Acturis) on achieving CSIO’s API Security Standards Certification for their Acturis ...

SAN FRANCISCO—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the ...

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

Alternative battery technologies, hybrid energy storage, and the use of AI-based solutions drive advances in battery energy ...